Therapies directed at the basic defect in cystic fibrosis

被引：8

作者：

Zeitlin, PL ^{[1
]}

机构：

[1] Johns Hopkins Hosp, Dept Pediat, Baltimore, MD 21287 USA

来源：

CLINICS IN CHEST MEDICINE | 1998年 / 19卷 / 03期

关键词：

D O I：

10.1016/S0272-5231(05)70097-6

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

There are over 600 unique mutations in the cystic fibrosis (CF) gene that can be classified in five general categories with respect to specific defect. Through basic research into the genetic and physiologic consequences of these mutations, it has become possible to design genotype-specific therapeutic strategies. New pharmaceutical agents are under development for the rescue of defective cystic fibrosis transmembrane conductance regulator mRNA or protein. Some of these compounds are undergoing study in CF patients in Phase I clinical trials. This article evaluates the current research directed at translating a basic molecular understanding of the disease into innovative new treatments.

引用

页码：515 / +

页数：13

共 84 条

[1] In vivo model of adeno-associated virus vector persistence and rescue [J].

Afione, SA ;

Conrad, CK ;

Kearns, WG ;

Chunduru, S ;

Adams, R ;

Reynolds, TC ;

Guggino, WB ;

Cutting, GR ;

Carter, BJ ;

Flotte, TR .

JOURNAL OF VIROLOGY, 1996, 70 (05) :3235-3241

[2] EVIDENCE OF LACK OF TOXICITY OF SODIUM PHENYLACETATE AND SODIUM BENZOATE IN TREATING UREA CYCLE ENZYMOPATHIES [J].

BATSHAW, ML ;

BRUSILOW, SW .

JOURNAL OF INHERITED METABOLIC DISEASE, 1981, 4 (04) :231-231

[3] Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial [J].

Bellon, G ;

MichelCalemard, L ;

Thouvenot, D ;

Jagneaux, V ;

Poitevin, F ;

Malcus, C ;

Accart, N ;

Layani, MP ;

Aymard, M ;

Bernon, H ;

Bienvenu, J ;

Courtney, M ;

Doring, G ;

Gilly, B ;

Gilly, R ;

Lamy, D ;

Levrey, H ;

Morel, Y ;

Paulin, C ;

Perraud, F ;

Rodillon, L ;

Sene, C ;

So, S ;

TouraineMoulin, F ;

Schatz, C ;

Pavirani, A .

HUMAN GENE THERAPY, 1997, 8 (01) :15-25

[4] MAGAININS - A NEW FAMILY OF MEMBRANE-ACTIVE HOST DEFENSE PEPTIDES [J].

BERKOWITZ, BA ;

BEVINS, CL ;

ZASLOFF, MA .

BIOCHEMICAL PHARMACOLOGY, 1990, 39 (04) :625-629

[5] GENE-THERAPY FOR CYSTIC-FIBROSIS USING E1-DELETED ADENOVIRUS - A PHASE-I TRIAL IN THE NASAL CAVITY - THE UNIVERSITY-OF-NORTH-CAROLINA AT CHAPEL-HILL [J].

BOUCHER, RC ;

KNOWLES, MR ;

JOHNSON, LG ;

OLSEN, JC ;

PICKLES, R ;

WILSON, JM ;

ENGELHARDT, J ;

YANG, YP ;

GROSSMAN, M .

HUMAN GENE THERAPY, 1994, 5 (05) :615-639

[6] Correcting temperature-sensitive protein folding defects [J].

Brown, CR ;

HongBrown, LQ ;

Welch, WJ .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (06) :1432-1444

[7] AMINO-ACID ACYLATION - MECHANISM OF NITROGEN-EXCRETION IN INBORN-ERRORS OF UREA SYNTHESIS [J].

BRUSILOW, S ;

TINKER, J ;

BATSHAW, ML .

SCIENCE, 1980, 207 (4431) :659-661

[8] PHENYLACETYLGLUTAMINE MAY REPLACE UREA AS A VEHICLE FOR WASTE NITROGEN-EXCRETION [J].

BRUSILOW, SW .

PEDIATRIC RESEARCH, 1991, 29 (02) :147-150

[9] RESTORATION OF NITROGEN HOMEOSTASIS IN A MAN WITH ORNITHINE TRANSCARBAMYLASE DEFICIENCY [J].

BRUSILOW, SW ;

FINKELSTIEN, J .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (10) :1336-1339

[10] Nucleotide transport through the cystic fibrosis transmembrane conductance regulator [J].

Cantiello, HF .

BIOSCIENCE REPORTS, 1997, 17 (02) :147-171

← 1 2 3 4 5 6 7 8 9 →